

Press release from Emotra AB (publ)
Göteborg, 6 February, 2022

Emotra AB (publ) announces that two members have notified the company that they will be resigning from the board of directors

Today, the 6 of February, 2022, Emotra AB (“Emotra” or “the Company”) is announcing that Roy Anderson and Martin Schalling have informed the board of directors that they for personal reasons will be resigning from the board, effective immediately.

The board of directors of Emotra is announcing that the board members Martin Schalling and Roy Anderson are choosing to resign from the board for personal reasons. They both state that they have very high workloads and that they did not fully understand the amount of work their involvement on Emotra’s board would entail. The board of directors will continue to work with two vacant seats until the annual shareholder meeting, which will be held on 18 May, 2022, at which a new board of directors will be elected.

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on 6 February, 2022, at 11:38 AM under the above contact’s supervision.

For further information about Emotra, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of neurological research mental health. The Company’s methods/products, NeuraMetrix TC and EDOR®, are unique, proprietary and patent-protected.*

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden
Tel: +46 732-34 41 93, www.emotra.se